Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 3 1Phase 1/2 1

Status

Active not recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4CNS 1

Conditions

Carcinoma, Renal Cell 6Kidney Neoplasms 4Neoplasm Metastasis 2Glioblastoma 1Clear-cell metastatic renal cell carcinoma 1

Interventions

pembrolizumab 11Nivolumab 7Sunitinib 6Cyclophosphamide 6aldesleukin 5Sorafenib 5Everolimus 5temsirolimus 4belzutifan 4atezolizumab 4Ipilimumab 4fludarabine 3cabozantinib 3Interferon-alpha 3Gene Expression Profiling 3Fluorouracil 3Docetaxel 3Cetuximab 3Busulfan 3valspodar 2sargramostim 2perifosine 2pazopanib 2ixabepilone 2entinostat 2ciforadenant 2belinostat 2Thiotepa 2Temozolomide 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Kidney Neoplasms × belzutifan × Clear all
NCT06234605 2026-01-15

A Study of HC-7366 in Combination With Belzutifan (WELIREGâ„¢) in Patients With Renal Cell Carcinoma

HiberCell, Inc.

Phase 1 Recruiting
80 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT05030506 2025-12-18

MK-6482-010

Merck Sharp & Dohme LLC

Phase 1 Active not recruiting
45 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02974738 2025-07-10

MK-6482-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting
120 enrolled
CNSGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Kidney Neoplasms, Neoplasm Metastasis

NCT02293980 2024-06-17

MK-3795-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting
110 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡